Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 718-725

  Schleypen, Julia S ^a,b   Baur, Nicole ^a   Kammerer, Robert ^a,b   Nelson, Peter J ^b   Rohrmann, Karl ^c   Gröne, Elisabeth F ^d   Hohenfellner, Markus ^e   Haferkamp, Axel ^e   Pohla, Heike ^a,b   Schendel, Dolores J ^a   Falk, Christine S ^a   Noessner, Elfriede ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; GRANZYME A; GRANZYME B; INTERLEUKIN 2; PERFORIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MALE; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL COUNT; CELL LINE; CYTOTOXINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GRANZYMES; HUMANS; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHENOTYPE; PORE FORMING CYTOTOXIC PROTEINS; RECEPTORS, IGG; SERINE ENDOPEPTIDASES;

EID: 32944454635     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0857     Document Type: Article

References (47)

1. Guinan PD, Vogelzang NJ, Fremgen AM, et al. Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol 1995;153:901-3.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002;52:23-7.
3. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993;46:446-54.
4. Bleumer I, Oosterwijk E, De MP, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol 2003;44:65-75.
5. Paradis V, Lagha NB, Zeimoura L, et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000;436:351-6.
6. Gohring B, Riemann D, Rebmann U, Heynemann H, Schabel J, Langner J. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-α-2 in combination with 5-FU. Urol Res 1996;24:297-303.
7. Gez E, Mekori T, Struminger L, et al. T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-α, 5-fluorouracil, and vinblastine. Cancer Invest 1999;17:259-63.
8. Wersall P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and α-IFN. Med Oncol 1995;12:69-77.
9. Kolbeck PC, Kaveggia FF, Johansson SL, Grune MT, Taylor RJ. The relationships among tumor-infiltrating lymphocytes, histopathologic findings, and long-term clinical follow-up in renal cell carcinoma. Mod Pathol 1992;5:420-35.
10. Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21.
11. Bromwich EJ, McArdle PA, Canna K, et al. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 2003;89:1906-18.
12. Nakano O, Sato M, Naito Y, et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001;61:5132-6.
13. Villegas FR, Coca S, Villarrubia VG, et al. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer 2002;35:23-8.
14. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000;88:577-783.
15. Coca S, Perez-Piqueras J, Martinez D, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-8.
16. van Herpen CM, van der Laak JA, de Vries I, et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005;11:1899-909.
17. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, Moretta A. Human natural killer cells: their origin, receptors and function. Eur J Immunol 2002;32:1205-11.
18. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004;23:255-9.
19. Yokoyama WM, Plougastel BF. Immune functions encoded by the natural killer gene complex. Nat Rev Immunol 2003;3:304-16.
20. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
21. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci U S A 2000;97:2731-6.
22. Mocikat R, Braumuller H, Gumy A, et al. Natural killer cells activated by MHC class I (low) targets prime dendritic cells to induce protective CD8 T cell responses. Immunity 2003;19:561-9.
23. Schleypen JS, Von Geldern M, Weiss EH, et al. Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int J Cancer 2003;106:905-12.
24. Guinan P, Sobin LH, Algaba F, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3.
25. Sobin LH, Wittekind C; International Union against Cancer. TNM classification of malignant tumours. 5th ed. New York: John Wiley and Sons; 1997.
26. Robson CJ. Staging of renal cell carcinoma. Prog Clin Biol Res 1982;100:439-45.
27. Vielhauer V, Anders HJ, Mack M, et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5-positive leukocytes. J Am Soc Nephrol 2001;12:1173-7.
28. Schendel DJ, Wank R, Dupont B. Standardization of the human in vitro cell-mediated lympholysis technique. Tissue Antigens 1979;13:112-20.
29. Schmid H, Cohen CD, Henger A, Schlondorff D, Kretzler M. Gene expression analysis in renal biopsies. Nephrol Dial Transplant 2004;19:1347-51.
30. Cohen CD, Grone HJ, Grone EF, Nelson PJ, Schlondorff D, Kretzler M. Laser microdissection and gene expression analysis on formaldehyde-fixed archival tissue. Kidney Int 2002;61:125-32.
31. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-40.
32. + high stage and effector functions. J Immunol 2004;172:88-96.
33. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001;97:3146-51.
34. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000;21:228-34.
35. Sivori S, Pende D, Bottino C, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-66.
36. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 1993;53:5613-6.
37. Whiteside TL. Down-regulation of ζ-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004;53:865-8.
38. Kim KM, Lee K, Hong YS, Park HY. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells. Exp Mol Med 2000;32:246-54.
39. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-40.
40. Ferlazzo G, Thomas D, Lin SL, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004;172:1455-62.
41. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003;24:603-19.
42. Wu X, Jin LP, Yuan MM, Zhu Y, Wang MY, Li DJ. Human first-trimester trophoblast cells recruit CD56bright. J Immunol 2005;175:61-8.
43. Cozar JM, Canton J, Tallada M, et al. Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal cell carcinoma. Cancer Immunol Immunother 2005;54:858-66.
44. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy. Cancer 1998;83:58-63.
45. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, Nakajima N. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg 1997;82:190-3.
46. Nakamura H, Kawasaki N, Hagiwara M, Saito M, Konaka C, Kato H. Cellular immunologic parameters related to age, gender, and stage in lung cancer patients. Lung Cancer 2000;28:139-45.
47. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer 2003;105:717-23.